샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737480

세계의 급성 간헐성 포르피린증 시장

Acute Intermittent Porphyria
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 367 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 급성 간헐성 포르피린증 시장은 2030년까지 540만 달러에 달할 전망

2024년에 470만 달러로 추정되는 세계의 급성 간헐성 포르피린증 시장은 분석 기간인 2024-2030년에 CAGR 2.3%로 성장하며, 2030년에는 540만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 혈액검사는 CAGR 1.8%를 기록하며, 분석 기간 종료시에는 230만 달러에 달할 것으로 예측됩니다. 요검사 분야의 성장률은 분석 기간에 CAGR 3.4%로 추정됩니다.

미국 시장은 130만 달러로 추정, 중국은 CAGR 4.4%로 성장 예측

미국의 급성 간헐성 포르피린증 시장은 2024년에 130만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년에 CAGR 4.4%로 추이하며, 2030년에는 100만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.9%와 1.7%로 예측됩니다. 유럽에서는 독일이 CAGR 1.2%로 성장할 것으로 예측됩니다.

세계 급성 간헐적 포르피린증 시장 - 주요 동향 및 촉진요인 요약

급성 간헐적 포르피린증이 희귀질환-희귀의약품 분야에서 주목받는 이유

급성 간헐적 포르피린증(AIP)은 포르호빌리노겐 탈아미나제라는 효소의 결핍으로 인해 독성 포르피린 전구체가 체내에 축적되는 희귀한 유전성 대사 질환입니다. 생명을 위협할 수 있는 신경장기 발작이 특징인 AIP는 보통 심한 복통, 구토, 구토, 근력저하, 정신착란, 경련 등의 증상을 보입니다. 이러한 발작은 호르몬의 변동, 특정 약물, 단식, 알코올, 감염 등의 요인에 의해 유발되는 경우가 많습니다. 이 질환의 복잡성, 예측 불가능성, 심각성을 고려할 때 조기 진단과 효과적인 질병 관리가 매우 중요하지만, 전 세계 대부분의 의료 시스템에서 아직은 매우 미흡한 실정입니다.

AIP는 희귀질환으로 유병률은 인구 100만 명당 5-10명 정도로 추정됩니다. 그러나 희귀질환에 대한 인식이 높아지고, 유전자 스크리닝 프로그램이 확대되고, 진단 프로토콜이 개선됨에 따라 AIP 사례에 대한 인식과 보고가 증가하고 있습니다. 또한 의료제도와 제약회사들이 정밀의료의 미충족 수요에 주목하는 가운데, AIP는 명확한 분자 병태생리와 표적치료의 가능성으로 주목받고 있습니다. 국가 희귀질환 프레임워크와 희귀질환 치료제 지정에 AIP가 포함된 것도 시장의 관심과 연구 자금을 끌어올리고 있습니다.

치료법과 유전자 연구의 발전은 어떻게 치료 경로를 형성하고 있는가?

AIP의 치료 혁신은 단순한 증상 관리가 아닌 근본적인 생화학적 장애를 다루는 표적 치료제의 승인과 현재 진행 중인 개발로 인해 촉진되고 있습니다. 헴아르기네이트나 동결건조 헤마틴과 같은 헤민 기반 치료는 급성 발작에 대한 표준 치료법으로, 헤모글로빈 풀을 보충하고 포르피린 전구체의 간 생성을 억제합니다. 그러나 정맥 투여, 부작용, 접근성 문제 등의 제약으로 인해 보다 환자 친화적인 예방적 대안의 필요성이 대두되고 있습니다.

가장 큰 돌파구는 RNA 간섭(RNAi) 기반 치료법의 개발입니다. 디보실란은 FDA와 EMA의 승인을 받은 RNAi 약물로, ALAS1(헴 생합성 경로의 업스트림에 있는 율동 효소)의 발현을 감소시킴으로써 AIP 발작의 빈도와 중증도를 감소시키는 예방적 치료법을 제공합니다. 피하 투여와 입증된 효능은 AIP 만성질환 관리에 새로운 장을 열었습니다. 유전자 치료와 mRNA 기반 기술도 차세대 시퀀싱을 통해 개인화된 돌연변이 특이적 치료 접근법이 현실화됨에 따라 장기적 또는 근본적인 치료법으로 검토되고 있습니다.

어떤 환자 니즈, 진단 과제, 임상적 우선순위가 더 나은 관리 솔루션에 대한 수요를 주도하고 있는가?

최근 발전에도 불구하고 AIP의 현황은 진단 지연, 오진, 단편적인 치료 경로에 의해 정의되고 있습니다. 과민성대장증후군, 간질, 정신질환 등 흔한 질환과 증상이 겹치기 때문에 환자는 확정 진단을 받기까지 여러 차례의 입원을 경험하는 경우가 많습니다. 이러한 진단 지연은 질병 부담 증가, 만성 신장질환 및 고혈압과 같은 장기적인 합병증, 삶의 질 저하로 이어지며, AIP를 보다 신속하고 정확하게 식별하기 위해 임상적 인식 개선, 조기 생화학 검사, 응급의료 프로토콜에 유전자 검사를 포함시켜야 한다는 요구가 높아지고 있습니다. 요구가 높아지고 있습니다.

환자 입장에서는 접근성이 좋고, 비침습적이며, 예방적인 치료법의 필요성이 중요합니다. 잦은 병원 방문, 제한된 전문의만 이용할 수 있는 점, 다학제적 지원의 부족은 AIP의 관리에 큰 혼란을 초래할 수 있습니다. 이 때문에 자가 관리 치료, 재택 치료 모델, 증상 추적 및 유발 요인 방지를 위한 디지털 건강 툴에 대한 관심이 높아지고 있습니다. 건강 옹호 단체들도 희귀하고 예측할 수 없는 질병과 공존하는 것이 정신건강에 미치는 영향에 대한 인식을 높이고 심리적 지원, 환자 교육, 생활 지도를 포함한 치료 계획에 대한 보다 종합적인 접근을 촉구하고 있습니다.

지역과 치료 채널을 초월한 급성 간헐성 포르피린증 시장의 성장 동력은 무엇인가?

급성 간헐성 포르피린증 시장의 성장을 촉진하는 것은 희귀질환 치료제의 발전, 희귀질환 치료제 시장 개발에 대한 전 세계적인 관심 증가, 분자진단 약품의 가용성 증가입니다. 북미, 특히 미국에서는 희귀질환 치료제 지정, 신속 승인, 재정적 혜택 등을 통한 규제 당국의 강력한 지원이 의약품 혁신을 촉진하고 있습니다. 또한 전문 치료 센터와 활발한 환자 등록의 존재도 연구와 시장 도입을 촉진하고 있습니다. 유럽에서는 독일, 영국, 북유럽 국가들의 의료 시스템이 AIP 치료 경로를 희귀질환 네트워크에 통합하여 첨단 치료법과 진단법에 대한 접근성을 향상시키고 있습니다.

아시아태평양은 인식 개선 캠페인, 진단 인프라 구축, 시장 확대의 대상 지역으로 점차 부상하고 있지만, 진단 부족이 여전히 큰 장벽으로 작용하고 있습니다. 일본과 한국은 정책적 지원과 희귀질환 연구에 대한 자금 지원 측면에서 선두를 달리고 있습니다. 라틴아메리카와 중동은 개발 초기 단계에 있지만, 질환에 대한 인식 개선을 위한 의학교육 프로그램 및 공동 연구 파트너십을 통해 진전을 보이고 있습니다.

시장 세분화에서는 급성 치료제(헤민제제 등)와 만성 예방 치료제(RNAi 치료제 등)가 시장을 주도하고 있습니다. 전문약국, 병원 외래진료소, 희귀질환센터가 주요 유통 채널입니다. 장기적인 치료 성과에 대한 실제 임상 데이터가 축적되고 유전자 표적 치료제 파이프라인이 발전함에 따라 AIP 치료의 전망은 소극적 위기관리에서 적극적 질병 억제로 진화할 것으로 예측됩니다. 이는 전 세계 급성 간헐성 포르피린증 시장이 희귀대사질환 치료제라는 광범위한 영역 내에서 빠르게 성숙해가는 부문으로 변모하는 전환점이 될 것입니다.

부문

진단(혈액검사, 요검사, DNA 검사, 혈청 검사), 치료(고나도트로핀 방출 호르몬 아날로그 제제, 예방적 헤마틴 주입), 최종 용도(병원, 클리닉, 연구 센터)

조사 대상 기업의 예(총 34건)

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Cardinal Health
  • Dicerna Pharmaceuticals
  • LabCorp
  • Lupin Ltd.
  • Mayo Clinic Laboratories
  • McKesson Corporation
  • Moderna, Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Quest Diagnostics
  • Recordati Rare Diseases
  • Sanofi Genzyme
  • Sun Pharmaceutical Industries Ltd.
  • Swedish Orphan Biovitrum AB(Sobi)

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.17

Global Acute Intermittent Porphyria Market to Reach US$5.4 Million by 2030

The global market for Acute Intermittent Porphyria estimated at US$4.7 Million in the year 2024, is expected to reach US$5.4 Million by 2030, growing at a CAGR of 2.3% over the analysis period 2024-2030. Blood Tests, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$2.3 Million by the end of the analysis period. Growth in the Urine Tests segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Million While China is Forecast to Grow at 4.4% CAGR

The Acute Intermittent Porphyria market in the U.S. is estimated at US$1.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Million by the year 2030 trailing a CAGR of 4.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Acute Intermittent Porphyria Market - Key Trends & Drivers Summarized

Why Is Acute Intermittent Porphyria Attracting Increasing Attention in the Rare Disease and Orphan Drug Space?

Acute Intermittent Porphyria (AIP) is a rare genetic metabolic disorder resulting from a deficiency of the enzyme porphobilinogen deaminase, leading to the accumulation of toxic porphyrin precursors in the body. Characterized by potentially life-threatening neurovisceral attacks, AIP typically presents with symptoms such as severe abdominal pain, vomiting, muscle weakness, confusion, and seizures. These episodic flare-ups are often triggered by factors like hormonal fluctuations, certain medications, fasting, alcohol, and infections. Given the complexity, unpredictability, and severity of the condition, early diagnosis and effective disease management are critical yet remain significantly underdeveloped in most global healthcare systems.

The rarity of AIP, with an estimated symptomatic prevalence of 5 to 10 cases per million population, places it firmly in the domain of orphan diseases. However, growing awareness of rare diseases, expanded genetic screening programs, and improved diagnostic protocols are increasing the recognition and reporting of AIP cases. Moreover, as health systems and pharmaceutical companies focus on unmet needs in precision medicine, AIP is gaining prominence due to its well-defined molecular pathology and potential for targeted therapies. The inclusion of AIP in national rare disease frameworks and orphan drug designations is helping drive market interest and research funding.

How Are Advancements in Treatment Modalities and Genetic Research Reshaping Therapeutic Pathways?

Therapeutic innovation in AIP has been catalyzed by the approval and ongoing development of targeted therapies that address the underlying biochemical disruption rather than just managing symptoms. Hemin-based treatments, such as heme arginate and lyophilized hematin, remain the standard of care for acute attacks, replenishing the heme pool and downregulating the hepatic production of porphyrin precursors. However, limitations including IV administration, side effects, and accessibility issues have highlighted the need for more patient-friendly and preventive options.

A major breakthrough has been the development of RNA interference (RNAi)-based therapies. Givosiran, an FDA- and EMA-approved RNAi drug, offers prophylactic treatment by reducing the expression of ALAS1-the rate-limiting enzyme upstream in the heme biosynthesis pathway-thereby decreasing the frequency and severity of AIP attacks. Its subcutaneous delivery and demonstrated efficacy have marked a new chapter in chronic disease management for AIP. Parallel advancements in gene therapy and mRNA-based technologies are also being explored for long-term or curative interventions, particularly as next-generation sequencing makes personalized and mutation-specific treatment approaches more viable.

What Patient Needs, Diagnostic Challenges, and Clinical Priorities Are Driving Demand for Better Management Solutions?

Despite recent progress, the AIP landscape is still defined by diagnostic delays, misdiagnosis, and fragmented care pathways. Patients often experience multiple hospitalizations before receiving a definitive diagnosis, due to symptom overlap with more common conditions like irritable bowel syndrome, epilepsy, or psychiatric disorders. This diagnostic latency contributes to increased disease burden, long-term complications such as chronic kidney disease or hypertension, and decreased quality of life. There is a growing call for enhanced clinical awareness, early biochemical screening, and integration of genetic testing into emergency care protocols to identify AIP more rapidly and accurately.

From a patient perspective, the need for accessible, non-invasive, and preventive therapies is critical. Frequent hospital visits for IV treatments, limited specialist availability, and a lack of multidisciplinary support can make AIP management highly disruptive. This is driving interest in self-administered treatments, home care models, and digital health tools for symptom tracking and trigger avoidance. Health advocacy organizations are also raising awareness about the mental health impacts of living with a rare and unpredictable illness, prompting a more holistic approach to treatment planning that includes psychological support, patient education, and lifestyle guidance.

What Is Driving the Growth of the Acute Intermittent Porphyria Market Across Geographies and Therapeutic Channels?

The growth in the acute intermittent porphyria market is driven by advancements in rare disease therapeutics, increased global focus on orphan drug development, and the rising availability of molecular diagnostics. In North America, particularly the U.S., strong regulatory support through orphan drug designation, fast-track approvals, and financial incentives is fostering drug innovation. The presence of specialized treatment centers and active patient registries also facilitates research and market adoption. In Europe, national health systems in Germany, the UK, and the Nordics are integrating AIP care pathways into rare disease networks, improving access to advanced therapies and diagnostics.

Asia-Pacific is gradually emerging as a target region for awareness campaigns, diagnostic infrastructure improvement, and market expansion, though underdiagnosis remains a significant barrier. Japan and South Korea are leading in terms of policy support and rare disease research funding. Latin America and the Middle East are in earlier stages of development but are seeing progress through medical education programs and collaborative research partnerships aimed at improving disease visibility.

Segment-wise, the market is driven by both acute management drugs (like hemin products) and chronic prophylactic treatments (such as RNAi therapeutics). Specialty pharmacies, hospital outpatient clinics, and rare disease centers are key distribution channels. As real-world data accumulates around long-term treatment outcomes and as gene-targeted therapies advance through the pipeline, the AIP treatment landscape is expected to evolve from reactive crisis management to proactive disease suppression. This marks a turning point for the global acute intermittent porphyria market-transforming it into a rapidly maturing segment within the broader rare metabolic disorder therapeutics domain.

SCOPE OF STUDY:

The report analyzes the Acute Intermittent Porphyria market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis (Blood Tests, Urine Tests, DNA Tests, Serum Tests); Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions); End-Use (Hospitals, Clinics, Research Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Cardinal Health
  • Dicerna Pharmaceuticals
  • LabCorp
  • Lupin Ltd.
  • Mayo Clinic Laboratories
  • McKesson Corporation
  • Moderna, Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Quest Diagnostics
  • Recordati Rare Diseases
  • Sanofi Genzyme
  • Sun Pharmaceutical Industries Ltd.
  • Swedish Orphan Biovitrum AB (Sobi)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Acute Intermittent Porphyria - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Awareness and Diagnostic Advances Fuel Early Detection of AIP Cases
    • Orphan Drug Designation and Incentives Promote R&D for Targeted Therapies
    • Growth in Genetic Testing Enables Carrier Screening and Family-Based Risk Stratification
    • Emergence of RNA Interference and Gene Therapy Approaches Strengthens the Pipeline
    • Expansion of Specialty Clinics and Rare Disease Networks Improves Patient Access
    • Regulatory Support for Accelerated Approvals Enhances Commercialization Timelines
    • Advances in Prophylactic Therapies Reduce Frequency and Severity of Acute Attacks
    • Increased Collaboration Between Biotech Firms and Academia Spurs Innovation
    • Health Economics Emphasis on Reducing Hospitalizations Strengthens Case for Preventive Drugs
    • Digital Health Tools Support Symptom Monitoring and Crisis Management in AIP Patients
    • Growth in Patient Advocacy Groups Enhances Awareness and Treatment Adherence
    • Expansion of Real-World Evidence Studies Improves Long-Term Outcome Tracking
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Intermittent Porphyria Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acute Intermittent Porphyria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Blood Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Urine Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Urine Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Urine Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for DNA Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for DNA Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for DNA Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Serum Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Serum Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Serum Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gonadotropin-Releasing Hormone Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gonadotropin-Releasing Hormone Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Gonadotropin-Releasing Hormone Analogues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Prophylactic Hematin Infusions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Prophylactic Hematin Infusions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Prophylactic Hematin Infusions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • JAPAN
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • CHINA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • EUROPE
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Acute Intermittent Porphyria by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • FRANCE
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • GERMANY
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Acute Intermittent Porphyria by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • INDIA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Acute Intermittent Porphyria by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Acute Intermittent Porphyria by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • AFRICA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제